Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase NA 2Phase 1 2Phase 3 1Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2Plasma cell 1

Conditions

Multiple Myeloma 129Recurrence 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms, Plasma Cell 15Neoplasms 12Lymphoma, Non-Hodgkin 12Lymphoma 12Leukemia, Myeloid, Acute 10Lymphoma, Large B-Cell, Diffuse 9Neoplasm Metastasis 8Leukemia 8Burkitt Lymphoma 8Immunoglobulin Light-chain Amyloidosis 7Hodgkin Disease 7Prostatic Neoplasms 6Leukemia, Biphenotypic, Acute 5Lymphoma, B-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Follicular 3Hematologic Diseases 3Colorectal Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Sarcoma 2Rectal Neoplasms 2

Interventions

Azacitidine 56Cyclophosphamide 44fludarabine phosphate 42fludarabine 37Decitabine 27venetoclax 26Cytarabine 25Tacrolimus 20Specimen Handling 18Filgrastim 18Busulfan 18Melphalan 17Whole-Body Irradiation 16Mycophenolic Acid 16Antilymphocyte Serum 14Granulocyte Colony-Stimulating Factor 12Clofarabine 12Biopsy 12Peripheral Blood Stem Cell Transplantation 11Injections 11Etoposide 11Methotrexate 10thymoglobulin 9Thiotepa 9Stem Cell Transplantation 9Lenalidomide 9decitabine and cedazuridine drug combination 8aldesleukin 8Sirolimus 8Nivolumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Myelodysplastic Syndromes × Dexamethasone × Clear all
NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Dana-Farber Cancer Institute

Phase 1 Recruiting
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03465540 2023-04-12

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Amgen

Phase 1 Terminated
24 enrolled 21 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡